ESR1 and breast cancer: While the subcutaneous xenograft model we used does not traditionally metastasize55–57, the increased aggression associated with low ER and E2 sensitivity in breast cancer was observed, with ER− LSCC reaching final tumor volumes more than twice as large as their ER+ LSCC counterparts regardless of estrogen supplementation.